Biohaven (NYSE:BHVN) Sees Unusually-High Trading Volume – What’s Next?

Biohaven Ltd. (NYSE:BHVN) saw strong trading volume on Wednesday . Approximately 1,719,094 shares changed hands during mid-day trading, a decline of 33% from the previous session’s volume of 2,547,931 shares.The stock last traded at $14.4680 and had previously closed at $14.38.

Biohaven News Roundup

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Up to $795 million in deal value: SK Biopharmaceuticals will pay Biohaven upfront and milestone payments totaling as much as $795 million, in addition to tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. The agreement improves Biohaven’s liquidity, reduces the company’s future development costs for the program and could extend its cash runway. Biohaven and SK Biopharmaceuticals licensing agreement
• Positive Sentiment: External validation of the epilepsy program: The global partnership gives SK Biopharmaceuticals commercialization rights while allowing Biohaven to retain royalty economics. Opakalim is in Phase 2/3 development for focal epilepsy, providing a significant potential value catalyst if clinical results are successful. Reuters Biohaven SK Biopharmaceuticals deal
• Positive Sentiment: Favorable legal ruling: Biohaven also received a favorable ruling in a trade-secret misappropriation lawsuit, improving its legal position and potentially supporting recovery related to the dispute. Biohaven favorable trade-secret ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026, as well as a separate obesity-program readout. These events could determine whether the partnership’s milestone payments and future royalty opportunity are realized. Biohaven epilepsy licensing deal and obesity trial readout

Analysts Set New Price Targets

A number of analysts recently weighed in on BHVN shares. Royal Bank Of Canada upped their target price on shares of Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 11th. Needham & Company LLC set a $11.00 price target on shares of Biohaven in a research note on Monday, June 29th. Bank of America reiterated an “underperform” rating and set a $11.00 price target (down from $12.00) on shares of Biohaven in a report on Monday, June 29th. TD Cowen reissued a “buy” rating on shares of Biohaven in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Biohaven currently has an average rating of “Moderate Buy” and a consensus price target of $18.94.

Biohaven Trading Down 5.1%

The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23. The firm has a market cap of $2.43 billion, a PE ratio of -3.47 and a beta of 1.26. The business has a fifty day moving average price of $14.79 and a 200 day moving average price of $11.86.

Biohaven (NYSE:BHVN) last posted its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Analysts forecast that Biohaven Ltd. will post -3.29 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Janus Henderson Group PLC raised its stake in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares in the last quarter. BlackRock Inc. acquired a new position in Biohaven in the second quarter valued at $196,574,000. Jupiter Topco LLC acquired a new position in Biohaven in the second quarter valued at $127,852,000. Suvretta Capital Management LLC grew its holdings in shares of Biohaven by 83.0% during the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock worth $116,140,000 after purchasing an additional 4,666,666 shares during the last quarter. Finally, Infinitum Asset Management LLC increased its position in shares of Biohaven by 267.6% during the fourth quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after purchasing an additional 4,550,000 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.